Challenges and strategies to combat resistance mechanisms in thyroid cancer therapeutics
Background: BRAFV600E and N/H/K RAS mutations and oncogenic kinase fusions
involving neurotrophin tyrosine receptor kinase (NTRK), RET, anaplastic lymphoma kinase …
involving neurotrophin tyrosine receptor kinase (NTRK), RET, anaplastic lymphoma kinase …
Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics.
ML Gild, M Bullock, V Tsang, RJ Clifton-Bligh… - …, 2023 - search.ebscohost.com
Abstract Background: BRAF< sup> V600E</sup> and N/H/K RAS mutations and oncogenic
kinase fusions involving neurotrophin tyrosine receptor kinase (NTRK), RET, anaplastic …
kinase fusions involving neurotrophin tyrosine receptor kinase (NTRK), RET, anaplastic …
Challenges and strategies to combat resistance mechanisms in thyroid cancer therapeutics.
ML Gild, M Bullock, V Tsang, R Clifton-Bligh… - … : Official Journal of the …, 2023 - europepmc.org
BRAF V600E and K/N/H RAS mutations and oncogenic kinase fusions involving NTRK,
RET, ALK and ROS1 have been identified as actionable targets in thyroid cancer. These …
RET, ALK and ROS1 have been identified as actionable targets in thyroid cancer. These …
Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics
ML Gild, M Bullock, V Tsang… - … : official journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Background: BRAF V600E and N/H/K RAS mutations and oncogenic kinase fusions
involving neurotrophin tyrosine receptor kinase (NTRK), RET, anaplastic lymphoma kinase …
involving neurotrophin tyrosine receptor kinase (NTRK), RET, anaplastic lymphoma kinase …